... WhatsApp

New Drug Shows Hope for Treating Fatty Liver Disease

You are here >> Home > Latest Updates > Liver Disease Updates > New Drug…

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT) 24-week results DOI 10.1016S0140-6736(25)02114-2

A condition called metabolic dysfunction-associated steatohepatitis (MASH) affects the liver. It happens when fat builds up in the liver and causes damage. Over time, this can lead to scarring (fibrosis) and even liver failure. Until now, treatment options have been limited.

A new drug called pemvidutide may offer help. In a recent study, people with moderate to severe MASH took this drug once a week for 24 weeks. Some received a low dose, some a higher dose, and others received a placebo (no real medicine).

More than half of the people who took pemvidutide had their liver disease improve. Their liver damage did not get worse. This was much better than the group that took the placebo. While the drug did not yet show strong effects on liver scarring, it helped clear the liver disease itself.

Most people who took pemvidutide had only mild or moderate side effects. Very few people stopped taking the drug because of problems.

This early study is promising. Pemvidutide may help treat MASH safely. Longer studies are planned to see if it can also help with liver scarring over time.

If you have fatty liver disease, speak with your doctor. New treatments like this may soon become available.

Rate this post
Dr. Harsh J Shah

Exclusive Health Tips and Updates

Dr Harsh Shah - GI & HPB Oncosurgeon in India
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.